BIOPHARMA CREDIT PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.846 USD | +0.24% |
|
+0.48% | +0.71% |
| May. 02 | BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg | MT |
| May. 02 | BioPharma Credit agrees USD400 million loan for oncology firm Novacure | AN |
Financials (USD)
| Sales 2022 | 218M | Sales 2023 | 136M | Capitalization | 1.09B |
|---|---|---|---|---|---|
| Net income 2022 | 182M | Net income 2023 | 108M | EV / Sales 2022 | 5.19 x |
| Net cash position 2022 | 121M | Net cash position 2023 | 135M | EV / Sales 2023 | 7.07 x |
| P/E ratio 2022 |
7.11
x | P/E ratio 2023 |
10.1
x | Employees | - |
| Yield 2022 |
7.37% | Yield 2023 |
8.33% | Free-Float | 88.48% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.24% | ||
| 1 week | +0.48% | ||
| Current month | +1.20% | ||
| 1 month | -3.64% | ||
| 3 months | -4.94% | ||
| 6 months | +0.24% | ||
| Current year | +0.71% |
1 week
0.84
0.85
1 month
0.830.89
Current year
0.830.94
1 year
0.810.94
3 years
0.811.05
5 years
0.701.07
10 years
0.701.13
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Investment Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Harry Hyman
CHM | Chairman | 67 | 17-02-26 |
Duncan Budge
BRD | Director/Board Member | 68 | - |
| Director/Board Member | - | 18-12-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 0.846 | +0.24% | 826,631 |
| 24-06-07 | 0.844 | +0.48% | 278,697 |
| 24-06-06 | 0.84 | 0.00% | 763,581 |
| 24-06-05 | 0.84 | -0.24% | 384,434 |
| 24-06-04 | 0.842 | 0.00% | 445,931 |
Delayed Quote London S.E., June 10, 2024 at 11:35 am EDT
More quotes
BioPharma Credit PLC is a United Kingdom-based specialist debt investor to the life sciences industry. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. It seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products. The Company may also invest in equity issued by a life sciences company, acquired directly from the life sciences company or in the secondary market. It will seek to create a diversified portfolio of investments by investing across a range of different forms of debt assets issued by a variety of borrowers. It has two wholly owned subsidiaries: BPCR Limited Partnership and BPCR GP Limited. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors, LP.
Sector
Closed End Funds
Calendar
2024-06-12
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.846
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| +0.71% | 1.03B | |
| +7.44% | 13.23B | |
| +16.59% | 9.88B | |
| +3.20% | 5.77B | |
| +8.13% | 5.31B | |
| +23.76% | 4.78B | |
| -7.01% | 4.62B | |
| +19.75% | 4.47B | |
| +1.53% | 4B | |
| +3.58% | 3.98B |
- Stock Market
- Equities
- BPCP Stock
